Puretech Health Plc (Puretech), a subsidiary of Royalty Pharma Plc, is a biotherapeutics company that discovers, develops, and commercializes drugs to treat lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders. The company is pipeline products include LYT-100 (deupirfenidone), targeting inflammation and fibrosis, lymphedema, and SARS-CoV-2 respiratory problems; LYT-200, a human monoclonal antibody for the treatment of pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC) and cholangiocarcinoma (CCA); and LYT-210, a gamma delta-1 T cell receptor against solid tumors. It is also evaluating LYT-300, oral allopregnanolone for neurological indications. Puretech works in collaboration with pharmaceutical and biotechnology companies to develop its products. Puretech is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
6 Tide Street, Suite 400, Boston, Massachusetts, 02210
Website
puretechhealth.com
Telephone
1 617 4822333
No of Employees
111
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PRTC (LON)
Revenue (2021)
$15.6M
-10.2%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
16.8%
(2021 vs 2020)
Market Cap*
$726.7M
Net Profit Margin (2021)
XYZ
7.4%
(2021 vs 2020)
* As of and is in US$
Puretech Health Plc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| LYT-100 - Inflammation and Fibrosis, Lymphedema and SARS-CoV-2 |
| LYT-200 - Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Financing Agreements | In April, the company along with ARCH Venture Partners, Sofinnova Investments, and Third Rock Ventures invested US$100 million in Seaport Therapeutics. |
| 2023 | Divestiture | In March, the company sold its interest in KarXT royalty to Royalty Pharma. |
| 2022 | Others | In October, the company terminated the agreement to merge with Nektar Therapeutics. |
Competitor Comparison
| Key Parameters | Puretech Health Plc | Boehringer Ingelheim International GmbH | Horizon Therapeutics Plc | United Therapeutics Corp | Sage Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Germany | Ireland | United States of America | United States of America |
| City | Boston | Ingelheim am Rhein | Dublin | Silver Spring | Cambridge |
| State/Province | Massachusetts | Rheinland-Pfalz | - | Maryland | Massachusetts |
| No. of Employees | 111 | 53,000 | 2,190 | 1,168 | 487 |
| Entity Type | Public | Private | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Christopher Viehbacher | Chairman | Executive Board | 2019 | - |
| Daphne Zohar | Chief Executive Officer; Director | Executive Board | 2005 | - |
| Bharatt Chowrira, Ph.D. | President; Director; Chief Business, Finance and Operating Officer | Executive Board | - | - |
| Simona Levi, Ph.D. | Chief Legal Officer; Corporate Secretary | Senior Management | 2021 | - |
| Julie Krop, M.D. | Chief Medical Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward